EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease

Jickky Palmae Sarathy, Min Xie, Chui Fann Wong, Dereje A Negatu, Suyapa Rodriguez, Matthew D Zimmerman, Diana C Jimenez, Ilham M Alshiraihi, Mercedes Gonzalez-Juarrero iD, Véronique Dartois iD, Thomas Dick iD

ACS Infectious Diseases · 2025

DOI: 10.1021/acsinfecdis.4c00948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2025. Verfasst von Jickky Palmae Sarathy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous, Lung Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusAnti-Bacterial AgentsMycobacterium Infections, NontuberculousLung DiseasesMoxifloxacinAnimalsMicrobial Sensitivity TestsMiceAdministration, OralRifabutinAzabicyclo CompoundsDrug Therapy, CombinationDrug CombinationsHumansFluoroquinolonesFemalebeta-Lactams

Stichwörter der Autor:innen

NTMbacterial cell deathbactericidal antibioticsdrug combinationsnontuberculous mycobacteriapost antibiotic effect

Substanzen

Anti-Bacterial AgentsMoxifloxacinRifabutinAzabicyclo CompoundsavibactamDrug CombinationsfropenemFluoroquinolonesbeta-Lactams

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
  • Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, P.O. Box 9086, Addis Ababa 1165, Ethiopia.
  • Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
  • Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey 07110, United States.
  • Department of Microbiology and Immunology, Georgetown University, Washington, District of Columbia 20057, United States.

ORCID-Profile: Mercedes Gonzalez-Juarrero, Véronique Dartois, Thomas Dick

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Cystic Fibrosis Foundation

Zitieren

APA

Sarathy, J. P., Xie, M., Wong, C. F., Negatu, D. A., Rodriguez, S., Zimmerman, M. D., Jimenez, D. C., Alshiraihi, I. M., Gonzalez-Juarrero, M., Dartois, V., & Dick, T. (2025). Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00948

Vancouver

Sarathy JP, Xie M, Wong CF, Negatu DA, Rodriguez S, Zimmerman MD, et al. Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease. ACS Infectious Diseases. 2025. doi:10.1021/acsinfecdis.4c00948

BibTeX
@article{Sarathy2025,
  author = {Sarathy, Jickky Palmae and Xie, Min and Wong, Chui Fann and Negatu, Dereje A and Rodriguez, Suyapa and Zimmerman, Matthew D and Jimenez, Diana C and Alshiraihi, Ilham M and Gonzalez-Juarrero, Mercedes and Dartois, Véronique and Dick, Thomas},
  title = {Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease},
  journal = {ACS Infectious Diseases},
  year = {2025},
  doi = {10.1021/acsinfecdis.4c00948}
}
Kostenlos starten →